Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of TGRX-814 monotherapy in hematologic malignancies
CTR20240015Phase 2Active
- Sponsor
- Tajirui
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TGRX-814 in hematopoietic malignancies, non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), sponsored by Tajirui. Started May 2024; status: active.
02
Drugs
TGRX-814
03
Conditions
hematopoietic malignanciesnon-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20240015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240015.